Log-in
Sign-up
Webcast
Clinical Trials
Library
Webcast
Clinical Trials
Library
Home
>
Clinical Trials
Molecules
전체
Edoxaban
Olmesartan
Prasugrel
Pravastatin
Mirogabalin
Ramosetron
Trastuzumab deruxtecan
Status
Select
Check All
Search
Recruiting
Completed
Not yet recruiting
Enrolling by invitation
Active, not recruiting
Suspended
Terminated
Withdrawn
Unknown status
Email
Saved trials
ACTIVE_NOT_RECRUITING
NCT05411887
Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab
2,845
Enrollment(s)
1
Study location(s)
OBSERVATIONAL (None)
Hyperlipidemias
Hypertension
NOT_YET_RECRUITING
NCT07116239
Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome
60
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (NA)
Nephrotic Syndrome
Hypoalbuminemia
RECRUITING
NCT05491200
Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients
1,656
Enrollment(s)
26
Study location(s)
INTERVENTIONAL (PHASE4)
ST Elevated Myocardial Infarction
Dual Antiplatelet Therapy
COMPLETED
NCT04284657
Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
1
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE2)
Autosomal Dominant Polycystic Kidney Disease
ACTIVE_NOT_RECRUITING
NCT03793478
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
65
Enrollment(s)
27
Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Acute Myeloid Leukemia
RECRUITING
NCT06262438
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
60
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE2)
Acute Myeloid Leukemia in Children
COMPLETED
NCT06772246
A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate
70
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE1)
Healthy Subjects
RECRUITING
NCT06172127
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
165
Enrollment(s)
36
Study location(s)
INTERVENTIONAL (PHASE2)
HER2-positive Breast Cancer
16
17
18
19
20